In the present study, miR-233 was predicted to bind with circGNG4, and miR-223 has been determined to inhibit prostate cancer progression by targeting ETS transcription factor ERG (ERG) and integrin subunit α 3 (ITGA3)/integrin subunit β 1 (ITGB1) signaling (Kurozumi et al., 2016; Wei et al., 2020). Here, ITGB1 is linked to prostate cancer.